SALES: $1.53 BN
QIAGEN begins development of next-generation systems for digital PCR and acquires the digital PCR assets of Formulatrix, Inc., a developer of laboratory automation solutions.
QuantiFERON-Plus is added to the diagnostic catalogue of the STOP TB Partnership’s Global Drug Facility, opening a new channel to reach countries with a high incidence of TB but limited resources.
QIAGEN and Illumina announce a 15-year partnership to broaden the use of NGS-based in vitro diagnostic kits to deliver insights for clinical decision-making.
Two new FDA-approved tests are added to QIAGEN’s companion diagnostic portfolio: The therascreen PIK3CA RGQ PCR Kit aids in identifying patients eligible for a new breast cancer therapy developed by Novartis and the therascreen FGFR RGQ RT-PCR Kit identifies urothelial cancer patients for Janssen Biotech’s newly approved FGFR kinase inhibitor.
SALES: $1.50 BN
QIAGEN moves into the rapidly growing syndromic testing market with the launch of the QIAstat-Dx point-of-care testing system.
Collaborations with more than 25 pharmaceutical and biotech companies to develop companion and complementary diagnostics to guide clinical decision-making, solidifies QIAGENs leading position in precision medicine.
The flagship QIAsymphony automation solution surpasses 2,300 cumulative placements globally.
QIAGEN partners with NeuMoDx Molecular Inc. to commercialize two new fully integrated automation systems for higher-throughput PCR testing in clinical laboratories.
SALES: $1.42 BN
QuantiFERON-TB Gold Plus gains regulatory approval from the U.S.Food and Drug Administration. QFT-Plus represents the fourth generation of the market leading blood test for detecting latent tuberculosis (TB) infection.
GeneReader NGS System gains momentum in next-generation sequencing with enhanced technology, favorable user experience and new gene panels.
QIAGEN acquires OmicSoft Corporation, with software enabling customers to better manage genomic data and compare findings against massive public data sets.
SALES: $1.34 BN
Screening with QuantiFERON-TB accelerates rapidly as the global fight against tuberculosis adopts early warning strategy of finding and treating latent TB.
QIAGEN’s end-to-end GeneReader NGS System captures 10% of market for new benchtop sequencers in oncology.
New core technologies serve fast-growing fields of liquid biopsies, single cells and microbiomes.
QIAGEN acquires Exiqon A/S, adding solutions to unlock insights from RNA in the fight against cancer and other diseases.
SALES: $1.28 BN
QIAGEN launches the GeneReader NGS System, the first complete Sample to Insight solution designed for any lab to deliver actionable insights.
With the launch of new genetic fingerprinting kits for forensic labs, QIAGEN is the first new entrant in more than 20 years in the U.S. market for STR test kits.
In Europe, QIAGEN receives the first-ever regulatory registration of a lung cancer companion diagnostic based on liquid biopsies.
Launch of QuantiFERON-TB Gold Plus, the fourth-generation of QIAGEN’s industry-leading test for tuberculosis (TB) infection.
NET SALES: $1.35 BN
With the acquisition of Enzymatics and launch of 14 new gene panels, QIAGEN further strengthens its offering of universal solutions for next-generation sequencing.
QIAGEN’s technologies play a key role in the fight against the devastating Ebola outbreak in Africa.
The U.S. Food and Drug Administration grants regulatory clearance for the QIAsymphony RGQ MDx, marking a milestone for QIAGEN’s global rollout of its flagship automation platform.
In line with its strategy to address the rapidly growing needs of customers to transform biological samples into valuable molecular insights, QIAGEN establishes the business area Bioinformatics.
NET SALES: $1.30 BN
QIAGEN acquires Ingenuity Systems and CLC Bio, creating leadership in solutions for analysis and interpretation of biological data.
The FDA approves QIAGEN’s therascreen EGFR test as a companion diagnostic for Gilotrif in patients with non-small cell lung cancer.
NET SALES: $1.26 BN
QIAGEN gains FDA approval for its KRAS test as companion diagnostic for Erbitux in metastatic colorectal cancer patients and achieves a milestone in personalized healthcare.
Start of a comprehensive initiative to develop complete next-generation sequencing workflow solutions for clinical applications.
QIAGEN restructures the company with the creation of two Business Areas – "Life Sciences" and "Molecular Diagnostics".
NET SALES: $1.17 BN
Acquisition of QuantiFERON technology that allows for the detection of many diseases far earlier than other methods.
QIAGEN acquires a majority stake in the French company Ipsogen and gains access to a leading portfolio of blood cancer tests.
Further expansion in Asia with new subsidiaries in India and Taiwan.
NET SALES: $1.09 BN EMPLOYEES: 3,600
NET SALES: $1.01 BN
QIAGEN enhances its portfolio with several PCR-based assay panels covering entire biological pathways and diseases, thereby strengthening its offering for pharmaceutical research.
QIAGEN acquires DxS Ltd., giving the company a leadership position in personalized healthcare.
QIAGEN’s technologies play a key role in the fight against the global Swine Flu pandemic.
With the real-time PCR cycler Rotor-Gene Q and QIAgility for automated assay setup, QIAGEN enables the automation of complete laboratory workflows from sample to result.
NET SALES: $893M EMPLOYEES: 3,000
Acquisition of Pyrosequencing, a detection technology that works on a single base-pair level and allows the identification of unknown DNA sequences or mutations. QIAsymphony SP launches as the first system in a series of modular instruments, designed to automate entire laboratory workflows.
NET SALES: $650M EMPLOYEES: 2,600
QIAGEN merges with Digene Corp., creating the market and technology leader in molecular diagnostics.
QIAGEN introduces QIAcube, a revolutionary platform which fully automates the processing of QIAGEN consumable products.
Net sales: $466m Employees: 1,800
QIAGEN acquires an assay technology which allows for the testing of multiple pathogens in a single run (“multiplexing”).
QIAGEN establishes its Asia regional headquarters in Shanghai.
NET SALES: $398M EMPLOYEES: 1,600
QIAGEN acquires a leading position in molecular diagnostics by adding various PCR-based molecular tests to its portfolio.
NET SALES: $380M EMPLOYEES: 1,300
QIAGEN’s QIAamp becomes the world’s first standalone product for sample preparation to receive the CE-mark.
NET SALES: $298M EMPLOYEES: 1,600
Relocation of US headquarters from Valencia, CA, to Germantown, MD.
NET SALES: $263M EMPLOYEES: 1,550
QIAGEN launches PAXgene, the first product that consolidates and integrates key steps of sample collection, stabilization and purification.
NET SALES: $158M EMPLOYEES: 900
PreAnalytiX, a joint venture with Becton, Dickinson and Company, is established.
NET SALES: $120M EMPLOYEES: 800
QIAGEN significantly expands its capabilities in automation.
NET SALES: $75M EMPLOYEES: 600
Initial Public Offering is completed on Deutsche Boerse, Frankfurt.
NET SALES: $54M EMPLOYEES: 450
QIAGEN N.V. (Holding) established in Venlo, The Netherlands.
Initial Public Offering is completed on NASDAQ, New York.
QIAGEN introduces the BioRobot 9600, its first bench-top workstation, which automates purification technologies.
NET SALES: $100,000 EMPLOYEES: 5
QIAGEN revolutionizes molecular biology by introducing the first "Plasmid-Kit". It reduces the time needed for the preparation of plasmids, ring-shaped DNA molecules from bacteria, from 2-3 days to 2 hours.
NET SALES: $0 EMPLOYEES: 2
QIAGEN (Diagen) is founded in Düsseldorf, Germany.